Lin BioScience Statistics

Total Valuation

Lin BioScience has a market cap or net worth of TWD 33.26 billion. The enterprise value is 31.39 billion.

Market Cap	33.26B
Enterprise Value	31.39B

Important Dates

The next estimated earnings date is Tuesday, May 19, 2026.

Earnings Date	May 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Lin BioScience has 82.73 million shares outstanding. The number of shares has increased by 4.46% in one year.

Current Share Class	82.73M
Shares Outstanding	82.73M
Shares Change (YoY)	+4.46%
Shares Change (QoQ)	+3.61%
Owned by Insiders (%)	19.07%
Owned by Institutions (%)	4.17%
Float	64.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.32
P/TBV Ratio	3.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-23.03
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-21.67

Financial Position

The company has a current ratio of 58.18, with a Debt / Equity ratio of 0.00.

Current Ratio	58.18
Quick Ratio	57.68
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-2,812.04

Financial Efficiency

Return on equity (ROE) is -16.93% and return on invested capital (ROIC) is -11.69%.

Return on Equity (ROE)	-16.93%
Return on Assets (ROA)	-11.54%
Return on Invested Capital (ROIC)	-11.69%
Return on Capital Employed (ROCE)	-11.36%
Weighted Average Cost of Capital (WACC)	5.51%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-55.33M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +237.45% in the last 52 weeks. The beta is 0.20, so Lin BioScience's price volatility has been lower than the market average.

Beta (5Y)	0.20
52-Week Price Change	+237.45%
50-Day Moving Average	400.18
200-Day Moving Average	309.44
Relative Strength Index (RSI)	46.63
Average Volume (20 Days)	726,711

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.86B
Pretax Income	-2.64B
Net Income	-1.36B
EBITDA	-2.83B
EBIT	-2.86B
Earnings Per Share (EPS)	-16.60

Full Income Statement

Balance Sheet

The company has 16.29 billion in cash and 22.81 million in debt, with a net cash position of 16.27 billion or 196.67 per share.

Cash & Cash Equivalents	16.29B
Total Debt	22.81M
Net Cash	16.27B
Net Cash Per Share	196.67
Equity (Book Value)	25.13B
Book Value Per Share	129.73
Working Capital	16.17B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.44 billion and capital expenditures -7.20 million, giving a free cash flow of -1.45 billion.

Operating Cash Flow	-1.44B
Capital Expenditures	-7.20M
Depreciation & Amortization	23.79M
Net Borrowing	-16.42M
Free Cash Flow	-1.45B
FCF Per Share	-17.51

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lin BioScience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.46%
Shareholder Yield	-4.46%
Earnings Yield	-4.10%
FCF Yield	-4.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1